Financial Performance - The company's operating revenue for 2019 was ¥3,007,255,155.40, an increase of 12.99% compared to ¥2,661,549,902.78 in 2018[29]. - The net profit attributable to shareholders for 2019 was ¥58,778,676.12, a decrease of 72.07% from ¥210,453,089.65 in 2018[29]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥25,303,716.63, down 86.65% from ¥189,569,930.80 in 2018[29]. - The net cash flow from operating activities increased significantly to ¥596,746,640.65, a 997.30% increase from ¥54,383,382.87 in 2018[29]. - The total assets at the end of 2019 were ¥5,298,938,738.35, a decrease of 27.23% from ¥7,282,045,242.65 at the end of 2018[30]. - The net assets attributable to shareholders increased by 7.14% to ¥2,978,032,577.39 from ¥2,779,607,076.90 at the end of 2018[30]. - The company reported a significant decline in basic and diluted earnings per share, both at ¥0.1428, down 72.86% from ¥0.5261 in 2018[29]. - The weighted average return on equity decreased to 2.07%, down 5.52% from 7.59% in 2018[29]. - The company recorded a net profit of ¥-98,334,357.78 in Q4 2019, contrasting with profits in the first three quarters[32]. - The net profit attributable to shareholders dropped to 5,877.87 million, a decline of 72.07% due to asset impairment provisions[89]. Stake and Investment Holdings - The company holds a 16.43% stake in Guangzhou Ruoyuchen Technology Co., Ltd.[17]. - The company has a 45% stake in Zhuhai Guangfa Lanzi Internet Fashion Industry Fund Management Co., Ltd.[17]. - The company owns 70% of Sichuan Milan Baiyu Medical Beauty Hospital Co., Ltd.[17]. - The company holds a 70% stake in Shenzhen Milan Baiyu Medical Beauty Clinic[17]. - The company has a 26.53% stake in Agabang & Company, a KOSDAQ listed company in South Korea[17]. - The company has a 20% stake in Dream Medical Group Co., Ltd. (DMG) through its subsidiary[17]. - The company has a 30% total stake in DMG, combining direct and indirect holdings[17]. - The company has a 9.1% stake in L&P Cosmetic Co., Ltd.[17]. - The company has a 23.64% contribution in Zhuhai Guangfa Internet Fashion Industry Fund (Limited Partnership)[17]. - Lancy Co., Ltd. holds 60% of Xi'an Milan Baiyu Medical Beauty Hospital Co., Ltd. and 70% of Sichuan Jingfu Medical Beauty Hospital Co., Ltd. and other subsidiaries[18]. Business Strategy and Market Presence - The company operates multiple high-end women's fashion brands, achieving a significant market presence with nearly 70% of its stores ranking in the top five sales in their respective malls[48]. - The private medical beauty service market is projected to reach RMB 261.2 billion by 2022, indicating strong growth potential in the "beauty economy" sector[53]. - The company has established 13 medical beauty institutions across key cities, focusing on high-quality service and advanced medical technology[49]. - Milan Baiyu, one of the company's medical beauty brands, has a 10,000 square meter facility in Chengdu, recognized as a leading 5A-level beauty hospital in China[49]. - The company has expanded into the green baby and children’s clothing sector, acquiring a major stake in Agabang, a well-known Korean children's clothing brand[54]. - The company aims to enhance the competitiveness of its medical beauty brands through resource integration and rapid market expansion[53]. - The medical beauty brand Jingfu has successfully entered four major markets, establishing a standardized operational system[50]. - The company’s multi-brand strategy allows for clear differentiation in style and target demographics, catering to various consumer preferences[48]. - The company is committed to becoming a leading player in the domestic medical beauty industry, focusing on advanced technology and brand promotion[53]. Research and Development - The company has a strong focus on R&D, holding 2 national invention patents, 28 software copyrights, and 12 design patents as of the reporting period[74]. - The company has established a strong R&D team with 294 personnel, including 15 overseas designers, focusing on both apparel and medical beauty sectors[122]. - The company has initiated 19 R&D projects in women's wear over the past three years, enhancing product quality and sales scale[124]. - The company is enhancing its design innovation capabilities to adapt to rapidly changing consumer demands in the mid-to-high-end women's clothing market[168]. Cash Dividend and Profit Distribution - The company reported a profit distribution plan of 1.2 CNY per 10 shares, based on a total of 442,445,375 shares[10]. - The cash dividend for 2019 amounted to 140,107,593.40 CNY, representing 238.36% of the net profit attributable to the parent company[181]. - The total distributable profit for 2019 was 313,915,076.25 CNY, with the cash dividend accounting for 100% of the profit distribution[182]. - The company has maintained a consistent cash dividend policy, with the 2018 cash dividend representing 47.52% of the net profit attributable to the parent company[181]. - The cash dividend for 2017 was 60 million CNY, which was 31.99% of the net profit attributable to the parent company[181]. - The company has not issued any bonus shares or capital reserve transfers during the reporting period[184]. - The cash dividend policy has been compliant with the company's articles of association and shareholder resolutions[179]. Challenges and Strategic Adjustments - In 2019, the company faced significant challenges due to the COVID-19 pandemic, impacting traditional offline operations during the peak consumption season[158]. - The company established a new retail strategy, enhancing online sales capabilities and integrating online and offline business models[158]. - The company is implementing refined management practices and increasing the proportion of online business to mitigate rising labor costs[164]. - The company is actively monitoring foreign exchange markets to mitigate risks associated with currency fluctuations from overseas investments[171]. Acquisitions and Partnerships - The company plans to fully acquire Langzi Medical by purchasing the remaining 41.19% equity through a share issuance[192]. - The company has committed to compensating for any shortfall in net profit for Langzi Medical for the years 2019 to 2021[192]. - The company established a new subsidiary, Shannan Mingyi, with a 60% ownership to acquire the brand, business, and assets of the subsidiary[198]. - The company acquired 60% of Xi'an Meilifang and 21% of Baoji Gao Yisheng, and established a new partnership with employees to control the new entity, Xin Nan Jingfu, with a 55% stake[198]. Financial Management and Stability - The company's financial expenses decreased by 41.35% to 105.74 million, effectively controlling financial costs[86]. - The asset-liability ratio improved to 30.44%, down 10.72 percentage points from the beginning of the year, indicating enhanced financial stability[87]. - The company has reported a significant decrease in other current assets due to adjustments in accounting standards, reflecting a strategic shift in asset management[62]. - The company has committed to avoiding related party transactions and ensuring fair pricing in any necessary transactions[187].

朗姿股份有限公司 2019 年第三季度报告全文 朗姿股份有限公司 2019 年第三季度报告 2019 年 10 月 1 朗姿股份有限公司 2019 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人申东日、主管会计工作负责人常静及会计机构负责人(会计主管 人员)蒋琼声明：保证季度报告中财务报表的真实、准确、完整。 2 朗姿股份有限公司 2019 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |---------------------------------------------------------------------|-------------------------------------------------------------|------------------ ...

Financial Performance - The company's operating revenue for the reporting period was RMB 1,397,820,308.75, representing a 7.72% increase compared to the same period last year [25]. - The net profit attributable to shareholders was RMB 89,125,335.61, a decrease of 20.18% year-on-year [25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 77,938,013.41, down 27.54% from the previous year [25]. - The net cash flow from operating activities was RMB 110,498,809.77, reflecting a decline of 19.07% compared to the same period last year [25]. - The total assets at the end of the reporting period amounted to RMB 6,989,196,141.33, a decrease of 4.02% from the end of the previous year [25]. - The net assets attributable to shareholders at the end of the reporting period were RMB 2,807,265,542.61, showing a 1.00% increase from the previous year [25]. - The basic earnings per share for the reporting period were RMB 0.2228, down 20.20% year-on-year [25]. - The company reported a financial gain of RMB 6,367,861.85 from entrusted investment management [28]. - The company received government subsidies amounting to RMB 9,219,410.33 during the reporting period [28]. Investment and Acquisitions - The company holds a 70% stake in several medical beauty hospitals, including Sichuan Milan and Shenzhen Milan, enhancing its presence in the medical aesthetics sector [15]. - The company has a 14.18% stake in the Jiangsu Zhonghan Chenhui Lanzi Equity Investment Fund, indicating its involvement in investment management [15]. - The company has made strategic investments in various subsidiaries, including a 76% stake in Beijing Lanzi Hanya Asset Management Co., Ltd., which reflects its commitment to expanding its asset management capabilities [15]. - The company has a 26.53% stake in Agabang & Company, a publicly listed company in South Korea, indicating its international investment strategy [15]. - The company invested approximately RMB 310 million to become the largest shareholder of the Korean children's clothing brand Agabang, expanding its reach into the infant and children's apparel market [35]. - The company has invested in and acquired over 10 mid-to-high-end maternal and infant brands through its stake in Akabang, which is a leading children's clothing and supplies brand in South Korea [44]. - The company completed the acquisition of 41.19% equity in Langzi Medical, with a transaction value of 138.0385 million CNY, issuing 15,303,598 shares to the seller [146]. - The company transferred 42% equity in Langzi Hanya Asset Management for 69.594 million CNY, reducing its ownership from 76% to 34% [148]. Market Presence and Strategy - The company emphasizes the importance of accurate financial reporting and has ensured the integrity of its financial statements through declarations from its management [4]. - The company has established a diversified portfolio of subsidiaries across various sectors, including fashion, medical aesthetics, and asset management, to enhance its market position [15]. - The company is focused on expanding its presence in the mid-to-high-end women's clothing market and developing a diversified fashion ecosystem [33]. - The company has established a strong presence in the mid-to-high-end women's wear market, ranking among the top five high-end women's brands in major retail enterprises in China [34]. - The company aims to create a multi-dimensional fashion resource-sharing ecosystem that integrates online and offline channels across its business segments [39]. - The company is actively involved in the medical beauty industry through its subsidiary Lanzi Medical, which holds a majority stake in multiple medical beauty clinics [15]. - The company has rapidly expanded its medical beauty services by acquiring stakes in renowned brands and establishing a network of clinics, enhancing its market presence [38]. - The company is focusing on improving design innovation capabilities to adapt to rapidly changing consumer demands in the mid-to-high-end women's clothing market [113]. Operational Risks and Management - The company reported a significant focus on risk management and has outlined potential risks and countermeasures in its operational analysis section [5]. - The company maintains a diversified brand strategy to mitigate operational risks and capture market share across different consumer segments [34]. - The company faces risks related to medical accidents and personnel turnover in the medical beauty sector, which are addressed through strict adherence to standards and an internal talent recruitment strategy [111]. - The company has established a centralized supply chain and management system, enhancing operational efficiency and reducing overall operating costs and risks [110]. Future Plans and Growth Strategies - The company has outlined its future plans and potential growth strategies, although these are subject to market risks and uncertainties [5]. - The company plans to continue expanding its market presence and enhancing its product offerings in the coming periods [66]. - The company plans to expand its sales terminals for the Akabong brand in China, moving from key cities like Beijing and Chengdu to other major cities [58]. - The company is expanding the Akabane brand's presence in China by enhancing its online and offline sales channels and building a dedicated R&D team [113]. Shareholder and Governance Matters - The company plans to distribute a cash dividend of 2.00 CNY per 10 shares (including tax), with a total cash dividend amounting to 87,014,148.80 CNY, representing 100% of the distributable profit [122][125]. - The total number of shares for the dividend distribution is based on 435,070,744 shares [122]. - The company's net profit for the first half of 2019 was 148,435,186.50 CNY, leading to a distributable profit of 227,403,275.46 CNY after accounting for previous undistributed profits [125]. - The company has committed to maintaining independence in business, assets, personnel, and finances, ensuring no potential risks to independence post-acquisition [127]. - The controlling shareholders have pledged to avoid any business activities that may compete with the company, both currently and in the future [127]. - The company has implemented an employee stock ownership plan, with a total of 9.33 million shares purchased, accounting for 4.665% of the total share capital [136]. - The average purchase price for the shares in the employee stock ownership plan was 21.31 yuan per share [136]. - The employee stock ownership plan was funded by 27.99 million yuan from employee contributions, with additional interest-free loans from the controlling shareholder [135]. Compliance and Regulatory Matters - The company has not reported any issues or other situations regarding the use and disclosure of raised funds [93]. - The company has not faced any penalties or corrective actions during the reporting period [133]. - The company has not undergone any bankruptcy reorganization during the reporting period [130]. - There were no significant litigation or arbitration matters during the reporting period [131]. - The company has not engaged in any significant contracts during the reporting period [159]. - The company does not belong to the key pollutant discharge units as published by the environmental protection department [160]. - The company has not initiated any targeted poverty alleviation work during the reporting period and has no subsequent plans [161]. Financial Health and Credit - The company's liquidity ratio increased to 166.61% from 154.32%, showing a 12.29% improvement year-over-year [194]. - The debt-to-asset ratio decreased to 38.75% from 41.17%, reflecting a 2.42% reduction compared to the previous year [194]. - The EBITDA interest coverage ratio rose by 33.10% to 3.82, primarily due to a reduction in interest expenses after repaying 900 million yuan in short-term financing notes at the end of 2018 [196]. - The company has maintained a 100% loan repayment rate and interest payment rate during the reporting period [196]. - The company's main credit rating remains at AA with a stable outlook, while the current bond rating is AAA [190]. - There were no overdue debts reported during the reporting period [197]. - The company has complied with all commitments outlined in the bond issuance prospectus and has not violated any relevant regulations [200].

Revenue and Profit - The company's revenue for Q1 2019 was ¥721,769,552.24, representing an increase of 11.78% compared to ¥645,702,079.45 in the same period last year[8]. - Net profit attributable to shareholders decreased by 12.54% to ¥52,767,437.94 from ¥60,332,100.90 year-on-year[8]. - The company's operating revenue for the current period reached ¥337,968,838.02, an increase of 13.8% compared to ¥297,001,503.65 in the previous period[50]. - The net profit for the current period was ¥31,554,800.34, up from ¥28,863,752.50 in the previous period, reflecting a growth of 5.9%[54]. - Total operating revenue for the first quarter was CNY 721,769,552.24, an increase of 11.76% compared to CNY 645,702,079.45 in the previous year[43]. - Net profit for the period was CNY 58,248,471.28, a decrease of 8.73% from CNY 63,490,564.56 in the same period last year[45]. Cash Flow - The net cash flow from operating activities increased significantly by 88.66% to ¥159,720,255.45 compared to ¥84,662,397.53 in the previous year[8]. - The cash flow from operating activities amounted to ¥159,720,255.45, an increase from ¥84,662,397.53 in the previous period, representing an increase of 88.5%[57]. - The company reported a total cash inflow from operating activities of 638,381,533.62 yuan, with a significant increase in cash receipts from sales[61]. - Total cash inflow from investment activities was 320,968,936.99 yuan, while cash outflow was 467,958,696.05 yuan, resulting in a net cash flow of -146,989,759.06 yuan[61]. - Cash inflow from financing activities totaled 30,000,000.00 yuan, down from 980,000,000.00 yuan in the previous period, leading to a net cash flow of -239,708,300.49 yuan[63]. Assets and Liabilities - The total assets at the end of the reporting period were ¥7,004,974,953.57, a decrease of 3.80% from ¥7,282,045,242.65 at the end of the previous year[8]. - Total liabilities decreased to ¥2,710,982,805.81 from ¥2,997,725,556.39, a reduction of approximately 9.59%[33]. - The company's total assets decreased to CNY 4,231,683,823.67 from CNY 4,370,656,472.91, representing a decline of 3.18%[42]. - The company reported a total liability of CNY 2,997,725,556.39, with current liabilities at CNY 2,373,821,698.74[66]. - Total current assets increased to ¥3,724,468,188.83 from ¥3,663,353,596.78, representing a growth of approximately 1.67%[31]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 24,308[12]. - The largest shareholder, Shen Dongri, holds 49.06% of the shares, totaling 196,255,500 shares[12]. - The total equity attributable to owners of the parent company increased to CNY 2,173,795,603.66 from CNY 2,142,240,803.32, a rise of 1.48%[42]. Expenses and Impairments - Total operating costs amounted to CNY 713,353,565.51, up from CNY 637,281,840.27, reflecting a year-over-year increase of 11.96%[43]. - Tax expenses increased by 75.21% compared to the same period last year, mainly due to increased value-added tax and corresponding additional taxes in the women's clothing sector[18]. - Asset impairment losses increased by 188.30% compared to the same period last year, primarily due to new inventory write-downs and bad debt provisions in the subsidiary Akabong[18]. - Research and development expenses for the quarter were CNY 15,726,350.63, with no prior year data available for comparison[43]. Financial Position - The weighted average return on equity was 1.89%, down from 2.23% in the previous year, reflecting a decrease of 0.34%[8]. - Basic earnings per share decreased by 12.53% to ¥0.1319 from ¥0.1508 in the same period last year[8]. - The total comprehensive income for the current period was ¥46,590,218.41, compared to ¥29,737,481.56 in the previous period, showing a significant increase[54]. - The company executed the new financial instrument standards on January 1, 2019, leading to a reclassification of available-for-sale financial assets[69]. Other Financial Metrics - Other non-current assets decreased by 96.53% compared to the beginning of the period, mainly due to adjustments in the financial statements according to new financial standards[18]. - Employee compensation payable decreased by 43.54% compared to the beginning of the period, primarily due to the payment of year-end bonuses accrued at the end of the previous year in the asset management sector[18]. - Estimated liabilities decreased by 91.08% compared to the beginning of the period, mainly due to the write-off of certain estimated liabilities accrued at the end of the previous year in the medical beauty sector[18].

Dividend Distribution - The company plans to distribute a cash dividend of 1.50 RMB per 10 shares (including tax) based on a total of 400,000,000 shares[6] - The cash dividend amount for 2018 was CNY 60,000,000, which is 100% of the distributable profit[155] - The cash dividend for 2017 was CNY 60,000,000, with a payout ratio of 31.99%[154] - The cash dividend for 2016 was CNY 20,000,000, with a payout ratio of 12.19%[154] - The net profit attributable to ordinary shareholders for the year 2018 was CNY 210,453,089.65, representing a 47.52% payout ratio for cash dividends[154] - The total number of shares for the cash dividend distribution was based on 400,000,000 shares, with a proposed cash dividend of CNY 1.50 per 10 shares[155] - The retained earnings after the cash dividend distribution for 2018 were CNY 93,811,607.61[155] Company Ownership and Investments - The company holds a 16.43% stake in Guangzhou Ruoyuchen Technology Co., Ltd.[13] - The company has a 70% ownership in Sichuan Milan and Shenzhen Milan medical beauty clinics[15] - The company has a 20% stake in Dream Medical Group Co., Ltd. (DMG) through its subsidiary Dream Korea Holdings Co., Ltd.[13] - The company has a 72.42% stake in Beijing Lancy Hanya Asset Management Co., Ltd.[15] - The company holds a 9.1% stake in L&P Cosmetic Co., Ltd.[13] - The company has a 45% stake in Zhuhai Guangfa Lancy Internet Fashion Industry Fund Management Co., Ltd.[13] - The company has a 70% ownership in multiple medical beauty clinics under the brand "Jingfu"[15] - The company has a 14.18% stake in Jiangsu Zhonghan Chenhui Lancy Equity Investment Fund (Limited Partnership)[15] - The company has a 58.81% stake in Lancy Medical Management Co., Ltd.[13] - The company holds a 26.53% stake in Akabang, a leading children's clothing brand in South Korea, which reported a net loss of 91.16 million yuan in 2018[46] Financial Performance - The company's operating revenue for 2018 was ¥2,661,549,902.78, representing a 13.10% increase from ¥2,353,265,951.40 in 2017[25] - The net profit attributable to shareholders for 2018 was ¥210,453,089.65, up 12.20% from ¥187,571,319.95 in 2017[25] - The net profit after deducting non-recurring gains and losses was ¥189,569,930.80, a significant increase of 29.22% compared to ¥146,700,426.79 in 2017[25] - The company's cash flow from operating activities decreased by 57.96% to ¥54,383,382.87 from ¥129,370,750.75 in 2017[25] - The total assets at the end of 2018 were ¥7,282,045,242.65, reflecting a 4.96% increase from ¥6,937,963,035.99 at the end of 2017[25] - The basic earnings per share for 2018 was ¥0.5261, an increase of 12.20% from ¥0.4689 in 2017[25] - The weighted average return on equity for 2018 was 7.59%, slightly up from 7.37% in 2017[25] - The company achieved a total revenue of 2.66 billion CNY in 2018, representing a year-on-year growth of 13.10%[60] - The overall net profit attributable to shareholders reached 210.45 million CNY, marking a growth of 12.20% year-on-year[60] Market Expansion and Strategy - The company has established a multi-industry interconnected fashion ecosystem, focusing on high-end women's fashion, green baby products, medical beauty, and asset management[35] - The Lancy brand has ranked among the top five high-end women's fashion brands in major retail enterprises in China for several consecutive years, with nearly 70% of its stores in top ten rankings within their malls[36] - The company invested approximately RMB 310 million to become the largest shareholder of the Korean children's clothing brand Agabang, expanding its reach into the baby and children's apparel market[37] - The Chinese maternal and infant market is projected to reach RMB 3 trillion by 2020, with a growing demand for branded and high-quality products[38] - The company has expanded its medical beauty services, acquiring 100% of the shares of "Gao Yisheng Medical Beauty," increasing its medical beauty institutions to ten[40] - The medical beauty industry in China is rapidly growing, with a focus on professionalization and standardization, and the company aims to become a leading player in the market within three to five years[40] - The company aims to create a fashion ecosystem that integrates online and offline resources across multiple fashion sectors, including women's fashion, children's products, and medical beauty[43] - The company is committed to expanding its children's business, leveraging the brand advantages of Agabang to enhance domestic market penetration[67] - The company aims to accelerate the national layout of its mid-to-high-end maternal and infant brand, Akabong, by utilizing existing channels and customer resources, targeting cities with consumption potential[135] Research and Development - The company holds 2 national invention patents, 28 software copyrights, 12 design patents, and 8 utility model patents as of the end of the reporting period[55] - The number of R&D personnel decreased by 12.90% to 297, while the proportion of R&D personnel to total employees was 9.07%[99] - The company has established 17 R&D projects over the past three years, focusing on enhancing fabric comfort and quality management[95] - The company has set up a "Talent Cultivation Class" to nurture young designers, aiming to inject fresh ideas into product development[144] Operational Challenges and Risks - The company faces risks from rising labor costs, with a 6% increase in the minimum wage in Beijing, impacting operational costs and profitability[138] - The company acknowledges the risks associated with medical accidents and personnel turnover in the medical beauty sector, emphasizing the need for strict adherence to standards and quality control[140] - The company is monitoring foreign exchange markets to mitigate risks associated with currency fluctuations due to its overseas investments[145] - The company is committed to enhancing its operational performance while managing risks, particularly in the context of macroeconomic and regulatory changes[142] Governance and Compliance - The company has committed to avoiding competition and reducing related party transactions as part of its governance[157] - The company has a long-term commitment to fulfill its promises regarding related party transactions and competition avoidance[157] - The company has maintained good compliance with its commitments as of the report date[157] - The company emphasizes investor protection and has established comprehensive governance structures to safeguard shareholder rights[200] Financial Adjustments and Reporting - The company has made adjustments to its financial reporting format, including the reclassification of research and development expenses[162] - The company has not experienced any non-operating fund occupation by controlling shareholders during the reporting period[161] - The company did not propose any cash dividend distribution plan for ordinary shares despite having a positive net profit[154] - The company has established new subsidiaries, including Langzi Hanya (Hong Kong) Investment Management Co., Ltd., to support business expansion[168] Asset Management and Investments - The asset management business started in June 2017, providing professional consulting services and participating in strategic investments through partnerships[41] - The asset management industry in China is experiencing rapid growth, driven by policy adjustments and increasing competition in asset management talent[42] - The establishment of a national-level postdoctoral research station by Langzi Hanya Asset Management Co., Ltd. aims to attract and retain high-level asset management talent[43] - The company's asset management business is expanding, with significant investments in equity investments by its subsidiary Langzi Hanya Asset Management[45] - Investment income reached 301,108,712.67 CNY, accounting for 132.37% of total profit, driven by asset management company project returns[103]

[Important Notice](index=2&type=section&id=Item%201.%20Important%20Notice) The Board of Directors, Supervisory Board, and senior management guarantee the truthfulness and completeness of this quarterly report, with all directors attending the review [Board of Directors' Statement](index=2&type=section&id=Board%20of%20Directors'%20Statement) The Board of Directors, Supervisory Board, and senior management affirm the quarterly report's truthfulness and completeness, with all directors present for review - The company's Board of Directors, Supervisory Board, directors, supervisors, and senior management guarantee the truthfulness, accuracy, and completeness of the quarterly report content and assume corresponding legal responsibilities[4](index=4&type=chunk) - All directors attended the Board of Directors' meeting to review this quarterly report[5](index=5&type=chunk) - The company's principal officer, head of accounting, and head of the accounting department guarantee the truthfulness, accuracy, and completeness of the financial statements[5](index=5&type=chunk) [Company Profile](index=3&type=section&id=Item%202.%20Company%20Profile) This section provides an overview of the company's key financial performance, asset status, and shareholder structure during the reporting period [Key Accounting Data and Financial Indicators](index=3&type=section&id=Item%201.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) The company achieved strong year-to-date revenue and net profit growth, despite a significant decrease in operating cash flow, reflecting robust performance with some liquidity pressure Key Financial Performance Indicators | Indicator | Year-to-Date | Y-o-Y Change | | :--- | :--- | :--- | | Operating Revenue (RMB) | 1,996,087,615.61 | 21.37% | | Net Profit Attributable to Shareholders (RMB) | 184,654,872.43 | 80.58% | | Net Profit Attributable to Shareholders (Excluding Non-Recurring Items) (RMB) | 169,122,851.03 | 112.96% | | Net Cash Flow from Operating Activities (RMB) | 44,036,589.11 | -56.85% | | Basic Earnings Per Share (RMB/share) | 0.4616 | 80.59% | | Weighted Average Return on Net Assets | 6.69% | 2.61% | Key Financial Position Indicators | Indicator | As of Report End | Change from Prior Year-End | | :--- | :--- | :--- | | Total Assets (RMB) | 8,123,166,357.04 | 17.08% | | Net Assets Attributable to Shareholders (RMB) | 2,809,735,784.07 | 4.95% | - Year-to-date, the company's total non-recurring gains and losses amounted to **RMB 15.53 million**, primarily from government subsidies and investment income[9](index=9&type=chunk) [Shareholder Information](index=4&type=section&id=Item%202.%20Shareholder%20Information) The company has 25,540 common shareholders, with a concentrated equity structure where the controlling family holds over 61%, though some major shareholder stakes are pledged - As of the end of the reporting period, the total number of common shareholders was **25,540**[12](index=12&type=chunk) - The company's top three shareholders, Shen Dongri, Shen Jinhua, and Shen Bingyun, are father/child relations, forming a concerted party, with a combined shareholding exceeding **61%**, ensuring stable control[12](index=12&type=chunk)[13](index=13&type=chunk) - Controlling shareholder Shen Dongri pledged **141,430,000 shares**, representing **72.06%** of his total holdings; the fifth-largest shareholder Jin Xin pledged **8,419,897 shares**, representing **96.21%** of his total holdings[12](index=12&type=chunk) [Significant Events](index=6&type=section&id=Item%203.%20Significant%20Events) This section details major financial changes, progress on significant events, fulfillment of commitments, annual performance forecasts, and investor relations activities [Analysis of Significant Changes in Financial Data and Reasons](index=6&type=section&id=Item%201.%20Analysis%20of%20Significant%20Changes%20in%20Financial%20Data%20and%20Reasons) Significant financial changes reflect strategic expansion in medical aesthetics and asset management, alongside increased liabilities from financing activities and higher procurement for women's wear - Goodwill increased by **59.2%** from the beginning of the period, primarily due to the acquisition of Gao Yisheng by subsidiary Langzi Medical Aesthetics, which also impacted the growth of prepayments, other receivables, and advances from customers[16](index=16&type=chunk) - Monetary funds, available-for-sale financial assets, and investment income significantly increased by **48.33%**, **182.08%**, and **241.93%** respectively, mainly due to investments and returns from subsidiary Langzi Hanyuan Asset Management[16](index=16&type=chunk) - Interest payable and financial expenses increased by **337.77%** and **249.94%** respectively, primarily due to increased interest expenses from the company's issuance of corporate bonds, short-term financing bills, and increased bank loans[16](index=16&type=chunk) - Accounts payable increased by **111.66%** from the beginning of the period, mainly due to increased procurement for winter clothing raw materials in the women's wear business[16](index=16&type=chunk) [Progress of Significant Events](index=6&type=section&id=Item%202.%20Progress%20of%20Significant%20Events) The company successfully redeemed RMB 528.55 million in short-term financing bonds and completed its 2018 semi-annual profit distribution plan - On August 14, 2018, the company completed the redemption of its first tranche of short-term financing bonds for 2017, with a total principal and interest payment of **RMB 528.55 million**[17](index=17&type=chunk) - The company's 2018 semi-annual profit distribution plan was fully implemented on October 18, 2018[17](index=17&type=chunk) [Fulfillment of Commitments](index=7&type=section&id=Item%203.%20Fulfillment%20of%20Commitments) Controlling shareholders and related parties consistently fulfilled long-term commitments regarding avoiding horizontal competition, regulating related-party transactions, and share lock-up - The company's actual controllers and related parties continue to fulfill long-term commitments made since January 20, 2011, regarding avoiding horizontal competition and reducing and regulating related-party transactions, with good performance[20](index=20&type=chunk) - Controlling shareholders and actual controllers Shen Dongri and Shen Jinhua fulfilled their commitments regarding share reductions, including the provision that no more than **25%** of shares can be transferred annually during their tenure[21](index=21&type=chunk) [2018 Annual Performance Forecast](index=8&type=section&id=Item%204.%202018%20Annual%20Performance%20Forecast) The company forecasts 2018 full-year net profit growth between 10% and 40%, driven by steady expansion in fashion women's wear and medical aesthetics businesses 2018 Annual Net Profit Forecast | Item | Value | | :--- | :--- | | 2018 Y-o-Y Change in Net Profit Attributable to Shareholders | 10.00% to 40.00% | | 2018 Net Profit Attributable to Shareholders Range (RMB million) | 206.33 to 262.60 | | 2017 Net Profit Attributable to Shareholders (RMB million) | 187.57 | - The primary reason for performance change is the company's continued advancement of its "Pan-Fashion Industry Interconnected Ecosystem" strategy, expecting steady growth in sales scale and operating performance for both fashion women's wear and medical aesthetics businesses[22](index=22&type=chunk) [Wealth Management Activities](index=9&type=section&id=Item%208.%20Wealth%20Management%20Activities) The company engaged in over RMB 2.1 billion in wealth management, primarily in bank products, with no overdue unrecovered amounts at period-end Wealth Management Overview | Fund Source | Wealth Management Transaction Amount (RMB million) | Outstanding Balance (RMB million) | Overdue Unrecovered Amount (RMB million) | | :--- | :--- | :--- | :--- | | Proprietary Funds | 1,919.32 | 209.65 | 0 | | Raised Funds | 219.10 | 138.50 | 0 | | **Total** | **2,138.42** | **348.15** | **0** | - The company holds significant non-guaranteed floating-rate wealth management products with partner banks including China Merchants Bank, Everbright Bank, and Bank of Communications[25](index=25&type=chunk) [Investor Relations Activities](index=9&type=section&id=Item%209.%20Investor%20Relations%20Activities) In late August 2018, the company actively engaged with the capital market, hosting institutional investors for two on-site research visits and disclosing related activity records - The company hosted on-site research visits from institutional investors on **August 27, 2018**, and **August 30, 2018**[26](index=26&type=chunk)[28](index=28&type=chunk)

朗姿股份有限公司 2018 年半年度报告全文 朗姿股份有限公司 2018 年半年度报告 2018 年 08 月 1 朗姿股份有限公司 2018 年半年度报告全文 2 朗姿股份有限公司 2018 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人申东日、主管会计工作负责人常静及会计机构负责人(会计主管 人员)王彤声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告涉及公司未来计划等前瞻性陈述。该等陈述不构成公司对投资者的 实质承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理解 计划、预测与承诺之间的差异。 公司在本报告"第四节经营情况讨论与分析"中"十、公司面临的风险和应对 措施"部分，详细描述了公司经营中可能存在的风险及应对措施，敬请投资者关 注相关内容。 公司经本次董事会审议通过的利润分配预案为：以 400000000 为基数，向 全体股东每 10 股派发现金红利 1 元（含税），送 ...

朗姿股份有限公司 2017 年第一季度报告正文 证券代码：002612 证券简称：朗姿股份 公告编号：2018-039 朗姿股份有限公司 2018 年第一季度报告正文 1 朗姿股份有限公司 2018 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人申东日、主管会计工作负责人常静及会计机构负责人(会计主管 人员)王彤声明：保证季度报告中财务报表的真实、准确、完整。 2 朗姿股份有限公司 2018 年第一季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 645,702,079.45 | 536,006,887.14 | 20.47% | | 归属于上市公司股东的净利润（元） | 60,332,100.90 | ...

朗姿股份有限公司 2017 年年度报告全文 2018 年 03 月 朗姿股份有限公司 1 2017 年年度报告 朗姿股份有限公司 2017 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人申东日、主管会计工作负责人常静及会计机构负责人(会计主管 人员)王彤声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本年度报告涉及未来发展规模和经营计划等前瞻性陈述，不构成公司对投 资者的实质承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应 当理解规划、计划、预测与承诺之间的差异。 公司未来可能面临的风险详见本报告第四节"经营情况讨论与分析"之"九、 公司未来发展的展望"中的相关描述，敬请广大投资者注意投资风险。 公司经本次董事会审议通过的利润分配预案为：以 400000000 为基数，向 全体股东每 10 股派发现金红利 1.50 元（含税），送红股 0 股（含税），不以公积 金转增股本。 2 | 目录 | | ...

朗姿股份有限公司 2017 年第三季度报告全文 朗姿股份有限公司 2017 年第三季度报告 2017 年 10 月 1 朗姿股份有限公司 2017 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人申东日、主管会计工作负责人常静及会计机构负责人(会计主管 人员)王彤声明：保证季度报告中财务报表的真实、准确、完整。 2 朗姿股份有限公司 2017 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 6,269,256,656.03 | | 4,422,922,295.80 | 41.74% | | 归属于上市公司股东的净资产（元） | 2,564,934,726.79 | | 2,463 ...